Welcome to Men's Health Focus.
Please log in or register to view the content of this site.
This website provides free access to a range of men’s health related resources and has been developed by EPG Online with an educational grant and assistance from Bayer HealthCare Pharmaceuticals. The content of this site is intended for doctors and other healthcare professionals.
As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.
Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.
- September 2014 - Long-term testosterone therapy is associated with a reduction in obesity parameters, improved metabolic syndrome and health-related quality of life in men with hypogonadism
- In an unselected cohort of hypogonadal men presenting with ED to a single urologist’s office, only 4% were of normal weight, 34% were overweight, and 62% were obese
- Only 3% had a normal WC (≤94 cm), 28% had an increased waist size (94–101.9 cm), and 69% had a substantially increased waist size (≥102 cm)
- At the end of the observation period (maximum 5 years) 96% of men had lost weight (mean loss 11.1 kg)
- 98% of men showed a reduction in WC with a mean decrease of 9.4 cm
- In the obese subgroup (n=162), mean weight loss was 12.8 kg and mean reduction in WC was 10.5 cm
- MetS parameters were measured in the same overall cohort:
- Lipid pattern improved with substantial and sustained reductions in total cholesterol, LDL and triglycerides, and an increase in HDL
- The total cholesterol to HDL ratio, a cardiovascular risk marker, declined from 6.84 to 4.09 over the course of the study
- Fasting glucose and HbA1c decreased suggesting improved glycemic control
- Both systolic and diastolic BP decreased significantly
- Long-term health-related quality of life was improved by TU treatment resulting from contributions of sustained improvements in erectile function (p<0.0001) and muscle and joint pain
- No increased risk of prostate cancer was observed; prostate cancer was seen in only 2.3% of TU treated hypogonadal men
- September 2014 - Effects of testosterone replacement therapy in men with hypogonadism
- Testosterone therapy has beneficial effects on:
- body composition (Increased muscle mass, reduced fat mass (both total and visceral fat)
- lipid profile (reduced LDL and triglycerides, increased HDL)
- cardiovascular function (reduced blood pressure and atherosclerosis)
- glucose metabolism (increased insulin sensitivity, reduced glucose and HbA1c levels)
- inflammatory parameters (reduction in levels of liver enzymes, CRP and inflammatory cytokines)
- longevity (reduced risk of mortality and improved survival)
- sexual function (increased libido, improved erectile function and ejaculatory function)
- quality of life (less fatigue and improvement in energy, mood, vitality)
- Several long-term registry studies demonstrate important key results:
- Testosterone therapy effectively restores physiological testosterone levels within the first 12 months and these restored testosterone levels are maintained with testosterone therapy throughout the entire study period, which at this point is up to 6 years.
- Long-term Testosterone therapy results in a marked and sustained reduction in body weight and waist circumference, BMI, CRP (C-reactive protein; an inflammatory biomarker), HbA1c and improves lipid profile by reducing total cholesterol, LDL and triglycerides while increasing HDL.
- It is especially notable that the long-term reductions in body weight, waist circumference and HbA1c keep progressing throughout 5 years, and further improve after each year of testosterone therapy.
- Safety of TRT
- The most common side effects of testosterone therapy are increases in hematocrit and PSA. However, these elevations occur within the first 12 months, and thereafter remain stable with continued testosterone therapy.
- 5 years of testosterone therapy also does not change the International Prostate Symptom Score (IPSS), maximum urinary flow (Qmax) rate, post-void residual (PVR) volume, or prostate size.
If you are a healthcare professional and would like to gain free access to menshealthfocus.com you must register or login with your EPG Online username and password.
For your information, the menshealthfocus.com website concentrates on the understanding, management and treatment of erectile dysfunction and hypogonadism. The website also provides extensive details on up-coming conferences as well as an extensive library of useful resource.
THIS WEBSITE (www.menshealthfocus.com) IS OWNED AND OPERATED BY EPG HEALH MEDIA (EUROPE) LTD.